Use of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders
A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.
1 . A pharmaceutical composition for treating one or more genetic diseases or disorders in a mammal characterized by an inflamed tissue, enflamed organ or both comprising allogeneic mesenchymal stem cells in an amount effective to treat the one or more genetic diseases or disorders in the mammal, formulated for intravenous or intraosseous administration wherein said mesenchymal stem cells are not genetically modified.
2 . The pharmaceutical composition of claim 1 , wherein the mesenchymal stem cells are HLA-matched or partially HLA-matched.
3 . The pharmaceutical composition of claim 1 , further comprising bone marrow cells.
4 . The pharmaceutical composition of claim 1 , wherein the mesenchymal stem cells are in an acceptable pharmaceutical carrier.
5 . The pharmaceutical composition of claim 4 , wherein the acceptable pharmaceutical carrier is a pharmaceutically acceptable liquid medium for injection.
6 . The pharmaceutical composition of claim 5 , wherein the liquid media is saline.
7 . The pharmaceutical composition of claim 1 , comprising about 50×106 mesenchymal stem cells.
8 . The pharmaceutical composition of claim 1 , comprising about 20×106 mesenchymal stem cells.
9 . A pharmaceutical composition for improving the function of dysfunctional tissue comprising isolated allogeneic mammalian mesenchymal stem cells in an amount effective to improve the function of the dysfunctional tissue, wherein said mammalian mesenchymal stem cells are not genetically modified; and wherein said composition is formulated for intravenous or intraosseous administration.
10 . The pharmaceutical composition of claim 9 , wherein the dysfunctional tissue is characterized by a genetic defect.
11 . The pharmaceutical composition of claim 10 , wherein the dysfunctional tissue is characterized by the expression or production of inflammatory mediators.
12 . The pharmaceutical composition of claim 9 , wherein the exogenous mesenchymal stem cells are HLA-matched or partially HLA-mismatched.
13 . The pharmaceutical composition of claim 11 , further comprising bone marrow cells.
14 . The pharmaceutical composition of claim 9 , wherein the mesenchymal stem cells are in an acceptable pharmaceutical carrier.
15 . The pharmaceutical composition of claim 14 , wherein the acceptable pharmaceutical carrier is a pharmaceutically acceptable liquid medium for injection.
16 . The pharmaceutical composition of claim 15 , wherein the liquid medium is saline.
17 . The pharmaceutical composition of claim 9 , comprising about 50×106 mesenchymal stem cells.
18 . The pharmaceutical composition of claim 9 , comprising about 20×106 mesenchymal stem cells.